TG THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
TG THERAPEUTICS, INC. (TGTX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $15.40 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $15.40M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $12.27M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $12.28M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $10.32M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits as first filed |
|---|---|---|
| 2025-12-31 | $15.40M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $12.27M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $12.28M 10-K · filed 2025-03-03 | |
| 2022-12-31 | $10.32M 10-K · filed 2024-02-29 | |
| 2021-12-31 | $32.36M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $22.38M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $4.68M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $4.39M 10-K · filed 2020-03-02 | |
| 2017-12-31 | $4.93M 10-K · filed 2019-03-01 | $4.93M 10-K · filed 2018-03-15 |
| 2016-12-31 | $12.92M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $12.09M 10-K · filed 2017-03-16 | |
| 2014-12-31 | $12.42M 10-K · filed 2016-03-15 | |
| 2013-12-31 | $10.97M 10-K · filed 2015-03-16 | |
| 2012-12-31 | $3.05M 10-K · filed 2014-03-07 | |
| 2011-12-31 | $1.74M 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |